Oxolinic acid
Chemical compound
- J01MB05 (WHO)
- 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline- 7-carboxylic acid
- 14698-29-4
Y
- 4628
- 4467
N
- L0A22B22FT
- D02301
N
- CHEBI:138856
N
- ChEMBL416755
N
- DTXSID1021089
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O
InChI
- InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)
N
- Key:KYGZCKSPAKDVKC-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Oxolinic acid is a quinolone antibiotic developed in Japan in the 1970s.[1][2] Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme DNA gyrase. It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice.[3]
See also
- Amfonelic acid
- Fluoroquinolone
References
- ^ JP Patent 49138244
- ^ Gleckman R, Alvarez S, Joubert DW, Matthews SJ (August 1979). "Drug therapy reviews: oxolinic acid". American Journal of Hospital Pharmacy. 36 (8): 1077–9. PMID 384788.
- ^ Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J (December 1998). "Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European Neuropsychopharmacology. 8 (4): 255–9. doi:10.1016/S0924-977X(97)00083-7. PMID 9928913. S2CID 22626555.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e